APPLICATION FOR MATERIAL LICENSE

U.S. NUCLEAR REGULATORY COMMISSION APPROVED BY OMB 3150-6120 Expires 5 21-67

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION. SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW

FEDERAL AGENCIES FILE APPLICATIONS WITH

U.S. NUCLEAR REGULATORY COMMISSION DIVISION OF FUEL CYCLE AND MATERIAL SAFETY, NMSS WASHINGTON, DC 20565

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS, IF YOU ARE LOCATED IN:

CONNECTICUT. DELAWARE DISTRICT OF COLUMBIA MAINE MARYLAND MASSACHUSETTS. NEW HAMPSHIRE NEW JERSEY NEW YORK PENNEYLVANIA. RHODE ISLAND. OR VERMONT, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION REGION I NUCLEAR MATERIAL SECTION B 631 PARK AVENUE KING OF PRUSSIA, PA 19406

ALABAMA, FLORIDA, GEORGIA, KENTUCKY, MISSISSIPPI, NORTH CAROLINA, PUERTO RICO, SOUTH CAROLINA, TENNESSEE, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION II MATERIAL RADIATION PROTECTION SECTION 101 MARIETTA STREET, SUITE 2900 ATLANTA, GA. 30323 IF YOU ARE LOCATED IN

ILLINDIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

U.S. NUCLEAR REGULATORY COMMISSION, REGION III MATERIALS LICENSING SECTION 799 ROOSEVELT ROAD GLEN BLLYN, IL 60137

ARKANSAS, COLORADO, IDAHO, KANSAS, LOUISIANA, MONTANA, NEBRASKA, NEW MEXICO, NORTH DAKDTA, OKLAHOMA, SGUTH DAKDTA, TEXAS, UTAH, OR WYOMING, SEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION IV MATERIAL RADIATION PROTECTION SECTION 611 RYAN PLAZA DRIVE, SUITE 1000 ARLINGTON TX 78011

ALASKA, ARIZONA, CALIFORNIA, HAWAII, NEVADA, OREGON, WASHINGTON, AND U.S. TERRITORIES AND POSSESSIONS IN THE PACIFIC, BEND APPLICATIONS TO

U.S. NUCLEAR REGULATORY COMMISSION, REGION V MATERIAL RADIATION PROTECTION SECTION 1450 MARIA LANE, SUITE 210 WALNUT CREEK, CA. 94696

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR IN STATES SUBJECT TO U.S. NUCLEAR REGULATORY COMMISSION JURISDICTION.	REGULATORY COMMISSION OL Y IF THEY WISH TO POSSESS AND USE LICENSED MATERIAL				
1. THIS IS AN APPLICATION FOR ICheck eppropriate item)	Z NAME AND MAILING ADDRESS OF APPLICANT (Include Zip Code)				
A. NEW LICENSE	Marymount Hospital				
B. AMENDMENT TO LICENSE NUMBER	12300 McCracken Rd.				
X C. MENEWAL OF LICENSE NUMBER 34-05382-01	Garfield Heights, OH 44125				
3. ADDRESS(ES) WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED					
SAME	8904050374 880401 REG3 LIC30 34-05382-01 PNU				
4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION	TELEPHONE NUMBER				
Vincent A. Gargaro, Universal Consul					
SUBMIT ITEMS & THROUGH 11 ON 8h x 11 PAPER. THE TYPE AND SCOPE OF INFORMATIO					
RADIOACTIVE MATERIAL Element and mass number, b. chemical and/or physical form, and c. meximum amount which will be possessed at any one time.	6 PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.				
7. INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING AND EXPERIENCE.	B TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.				
8. FACILITIES AND EQUIPMENT	10. RADIATION SAFETY PROGRAM.				
11. WASTE MANAGEMENT	12 LICENZEE FEES (See 10 CFR 170 and Section 170 31) FEE CATEGORY 7 C AMOUNT ENCLOSED \$ 580.00				
13 CERTIFICATION (Must be completed by applicant) THE APPLICANT UNDERSTANDS THA BINDING UPON THE APPLICANT	T ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE				
THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF O PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS PART IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF	F THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS S 30, 32, 33, 34, 35, AND 40 AND THAT ALL INFORMATION CONTAINED HEREIN.				
WARNING 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 BZ STAT 749 MAKES IT A C TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WIT	RIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION HIN ITS JURISDICTION				
SIGNATURE-CERTIFYING OFFICER TYPED/PRÎNTED NAME	President DATE				
Thomas June Thomas J. Trudell	and Chief Executive Off. 9-9-87				
ANNUAL RECEIPTS D. NUMBER OF EMPLOYEES (Total for	d WOULD YOU BE WILLING TO FURNISH COST INFORMATION (Joiler and/or staff hours)				
<\$250K \$1M-3.5M entire facility excluding outside contractors)	ON THE ECONOMIC IMPACT OF CURRENT NRC REGULATIONS OR ANY FUTURE PROPOSED NRC REGULATIONS THAT MAY AFFECT YOU? (NRC regulations parmit				
\$260K-600K \$3.6M-7M	if to protect confidences commercial or financial -proprietary -information furnished to the ejency in confidences)				
\$600K750K \$7M-10M ENUMBER OF BEDS					
\$750K-1M >\$10M	YES. NO				
b management provides a second	USE ONLY				
TYPE OF FEE OF FEE LOG THE FEE CATEGORY COMMENTS	SEP 2 4 1987				
2580 CHECK NUMBER CONTROL NO. 0	SEP 2 4 1987 PATE / /8/				

PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on NRC Form 313. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

- AUTHORITY: Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
- PRINCIPAL PURPOSE(S): The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR
 Parts 30, 32, 33, 34, 35 and 40 to determine whether the application meets the requirements of the Atomic Energy Act of
 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment
 thereof.
- 3. ROUTINE USES: The information may be (a) provided to State health departments for their information and use; and (b) provided to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriate Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for an NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you.
- 4. WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION: Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed. A request
 that information be held from public inspection must be in accordance with the provisions of 10 CFR 2.790. Withholding from public inspection shall not affect the right, if any, of persons properly and directly concerned need to inspect
 the document.
- SYSTEM MANAGER(S) AND ADDRESS: U.S. Nuclear Regulatory Commission
 Director, Division of Fuel Cycle and Material Safety
 Office of Nuclear Material Safety and Safeguards
 Washington, D.C. 20555

MARYMOUNT NRC

By Product Material	Amount	Purpose
5.a. Material in 31.11	as needed	6.a. in Vitro testing
5.b. Material in 35.100	as needed	6.b. Medical Use
5.c. Material in 35.200	as needed	6.c. Medical Use
5.c. Material in 35.300	as needed	6.d. Medical Use

Items #5 & 6 Prepared: 8/17/87

AU'	THORIZED USERS	BY PROI	OUCT MATE	ERIAL
√1.	NORBERT REICH, D.O.	31.11, 35.300	35.100,	35.200
J2.	PAUL JANICKI, M. D.	31.11, 35.300	35.100,	35.200
V3.	FRANK E. SEIDLEMANN, D.O.	31.11, 35.300	35.100,	35.200
14.	CHRISTINE A. QUINN, M.D.	31.11, 35.300	35.100,	35.200
5.	BYUNG H. WOO, M.D.	31.11, 35.300	35.100,	35.200
16.	THOMAS HAVRILLA, M.D.	31.11, 35.300	35.100,	35.200
17.	GUY SYVERTSEN, D.O.	31.11, 35.300	35.100,	35.200
/ 8.	CLAUDIA ROZUK, M.D.	31.11, 35.300	35.190,	35.200
-9.	CHRISTINE H. ECKHAUSER, M.D.	31.11, 35.300	35.100,	35.200

For training and experience for users listed 1-7, refer to NRC license #34-05382-01.

For Claudia Rozuk, M.D. refer to NRC license #34-01334-02.

See attached for Christine H. Eckhauser, M.D.

Item #7
Prepared: 8/17/87

(9-21)

AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Christine H. Eckhauser, M.D.

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE

	3. CEPTIFICATION	
SPECIALTY BOARD	CATEGORY	MONTH AND YEAR CERTIFIED

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

		TYPE AND LENG	TYPE AND LENGTH OF TRAINING		
FIELD OF TRAINING	LOCATION AND DATE (S) OF TRAINING	LECTURE/ LABORATORY COUNSES (HOLIS)	SUPERVISED LABORATORY EXPERIENCE (Hears)		
a. FIADIATION PHYSICS AND INSTRUMENTATION	University Hospitals of Cleveland Cleveland, Ohio 44106	90	20		
b. RADIATION PROTECTION	,,	30	10		
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	"	90	15		
d. RADIATION BIOLOGY	n .	50	10		
e. RADIOPHARMACEUTICAL CHEMISTRY	н	40	5		

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

SOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
1-131	200 mCi	University Hospitals of Cleveland	3 months	Clin.Dx. & Rx
1'c-99m	1000 mCi	"	"	Clin.Dx.
P-32	30 mCi	' "	11	"
Others	10 mCi	"	11	"

PRECEPTOR STATEMENT

Supplement it must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, optain a separate statement from each.

1. APPLICANT PHYSICIAN'S HAME AND ADDRESS

FULL NAME

Christine H. Eckhauser, M.D.

STREET ADLRESS

56 Lyman Circle

CITY

STATE ZIP CODE

Shaker Heights, Ohio 44122

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST UF:

- Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the petient including calculation of the radiation dose, related measurements and plutting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

(fb/F	2. CLINICAL TRAINING AN	and an experimental process of the second process of the second party of the second pa	BOVE NAMED PHYSICIAN
ISOTUPE	CONDITIONS DIAGNOSED OF TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate times.)
	DIAGNOSIS OF THYROID FUNCTION	80	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
4-131	LIVER FUNCTION STUDIES		
1-125	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	54	
	IN VITRO STUDIES		
OTHER			
1-125	DETECTION OF THROMBOSIS		
1-131	THYROID IMAGING	81	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCRE AS IMAGING		
Yb-169	CISTERNOGRAPHY	9	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	33	
COTMER R	Kidney Circulation	47	
	BRAIN IMAGING	84	
Pro I	CARDIAC IMAGING	7/	
ille s	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
Tc-99m	BLOOD POOL IMAGING	11	
	PLACENTA LOCALIZATION .		
P. 12	LIVER AND SPLEEN IMAGING	270	
	LUNG IMAGING	51	
	BONE IMAGING	380	
OTHER			

CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

OFOPE	ONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	2	
P-32 (Colbidal)	INTPACAVITARY TREATMENT		
1-131	TREATMENT OF THYROID CARCINOMA		are
1-131	TREATMENT OF HYPERTHYROIDISM	5	50013 %
Au- 198	INTRACAVITARY TREATMENT		Not sounded horasid
Co-60	INTERSTITIAL TREATMENT		Del o 15 13 60 granding
Or C#137	INTRACAVITARY TREATMENT		121 Min 84 3+
1-125 0/ (r-192	INTERSTITIE TREATMENT		110 111 3 P
Co-60 or Cr-137	TELETHERAPY TREATMENT		
5490	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	5	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	5	
Other Ga 67 T1201 Co 57	Gallium Thallium Cardiac Schillings	22 8 12	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

January 1981, February 1979 and March 1979

Total hours = 624

4.	THE	TRAINING AND EXPERIENCE INDICATED ABOVE	& PRECEPTOR'S S
	WAS	ORTAINED LINDED THE SUPERVISION OF	

& NAME OF SUPERVISOR

Abbas M. Rejali, M.D.

& NAME OF INSTITUTION

University Hospitals of Cleveland

& MAILING ADDRESS

2074 Abington Road

Cleveland, Ohio 44106
5. MATERIALS LICENSE NUMBER(S)

34-05469-01

GNATURE

Abbas M. Rejali, M.D.

8. DATE

May 8, 1987

NRC FORM 313M SUPPLEMENT B (9-61)

GPO 890-813

Training for individuals working in or frequenting Restricted areas.

We will establish and implement the model training program that was published in Appendix A to Regulatory guide 10.8, Revision 2.

Ancillary personnel, e.g nursing, clerical, housekeeping, security, maintenance whose duties may require them to work in the vicinity of radioactive material will be given the opportunity to be informed about radioactive hazards and appropriate precautions.

Personnel will be instructed:

- 1. Before assuming duties with, or in the vicinity of, radioactive material.
- 2. During annual refresher training.
- 3. Whenever there is a significant change in duties, regulations, or in the terms o' the license.

item #8 Prepared:8/17/87 Facilities and Equipment

- 9.2 Survey meters will be calibrated by Universal Consultants, Inc., NRC license #34-20327-01.
- 9.3 We will establish and implement the model procedure for calibrating our dose calibrator that was published in the Appendix C to regulatory guide 10.8, Revision 2.
- 9.4 We will establish and implement the model personnel external exposure monitoring program published in the Appendix D to regulatory guide 10.8, revision 2.

Item #9 Prepared: 8/17/87

Partial First Floor Plan - H.V.A.C. Nuclear Med. Unit scale: 1/4": 1'-0"



9

- 10.1 We will establish and implement the model procedure for establishing and operating a Radiation Safety Committee that was published in Appendix F to regulatory guide 10.8, Revision 2.
- 10.2 We will establish and implement the model ALARA program that was published in Appendix G to regulatory guide 10.8, Revision 2.
- 10.3 Leak test will be performed by U.C.I., license #34-20327-01.
- 10.4 We will establish and implement the model safety rules that was published in Appendix I guide 10.8, Revision 2.
- 10.5 We will establish and implement the model spill procedures published in Appendix J guide 10.8, Revision 2.
- 10.6 We will establish and implement the model guidelines for ordering and receiving radioactive material that was published in Appendix K guide 10.8, Revision 2.
- 10.7 We will establish and implement the model procedures for opening packages that was published in Appendix L guide 10.8, Revision 2.
- 10.8 We will establish and implement the model procedure for unit dosage record system that was published in Appendix M.1 guide 10.8, Revision 2.
- 10.9 We will establish and implement the procedure for multidose vial record that was published in Appendix M.2 guide 10.8, Revision 2.
- 10.10 We will establish and implement the model procedure for measuring and recording molybdenum concentrations that was published in Appendix M.3 guide 10.8, Revision 2.

10.11 N/A

10.12 We will establish and implement the model procedure for area surveys that was published in Appendix N guide 10.8, Revision 2.

10.13 N/A

10.14 We will establish and implement the model procedure for radiation safety during radiopharmaceutical therapy that was published in Appendix P guide 10.8, Revision 2.

10.15 N/A

Item #10 Prepared: 7/18/87 11.1 We will establish and implement the general guidance and model procedure for waste disposal that were published in Appendix R guide 10.8, Revision 2. The used radiopharmaceuticals may be returned to Central radiopharmacy.

For items 5 through 11 refer to attached sheets.

Item #11
Prepared: 7/18/87

DFC 2.9 1986 Marymount Hospital ATTN: Thomas J. Trudell President and Chief Executive Officer 12300 McCracken Boulevard Garfield Heights, OH 44125

Gentlemen:

Enclosed is Amendment No. 33 to your NRC License No. 34-05382-01 in accordance with your request.

Please note the Subitems 6.C., 7.C., 8.C., and 9.C., pertaining to xenon-133 use at your facility have been deleted as requested.

Please review the enclosed document carefully and be sure that you understand all conditions. You must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

- Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Padiation," and other applicable regulations.
- Possess radioactive material only in the quantity and form indicated in your license.
- Use radioactive material only for the purpose(s) indicated in your license.
- Notify NRC in writing of any change in mailing address.
- Request and obtain appropriate amendment if you plan to change ownership of your organization, change locations of radioactive material, or make any other changes in your facility or program which are contrary to your license conditions or representations made in your license application and any supplemental correspondence with NPC. Any amendment request should be accompanied by the appropriate fee specified in 10 CFR Part 170.

8704010587 B61229 REG3 LIC30 34-05382-01

NRC FORM 313M (9-81)

U.S. NUCLEAR REGULATORY COMMISSION APPLICATION FOR MATERIALS LICENSE - MEDICAL

Approved by OMB 3150-0041

(9-81) 10 CFR 35

INSTRUCTIONS - Complete Items 1 through 26 if this R ari initial application or an application for renewal of a license. Use supplemental sheets where necessary. Item 26 must be completed on all applications and signed. Retain one copy. Submit original and one copy of entire application to: Director, Office of Nuclear Materials Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Upon approval of this application, the applicant will receive a Materials License. An NRC Materials License is issued in accordance with the general requirements contained in Title 10, Code of Federal Regulations, Part 30, and the Licensee? subject to Title 10, Code of Federal Regulations, Parts 19, 20 and 35 and the license fee provision of Title 10, Code of Federal Regulations, Part 170. The license fee category should be stated in Item 26 and the appropriate fee enclosed.

6.a. RADIOACTIVE MATERIAL FOR	MEDICA	MAXIMUM	П	MARK	MAXIMUM
Refer to attached It			Frank Seidelman, D.O. Physics Services as Co		
 INDIVIDUAL USERS (Name individuals supervise use of radioactive material. Completor each individual.) 	ete Suppli	ements A and B	5. RADIATION SAFETY OFFICER (RSC as radiation safety officer. If other than indi- me of training and experience as in Suppleme	ridual user, com nt A.)	plete resu-
PERSON TO CONTACT REGARDING THE W. Christopher Wagne NMA Medical Physics TELEPHONE NO.: AREA CODE (216)	r, Co Servi	nsultant ces	3. THIS IS AN APPLICATION FOR: (C.) NEW LICENSE DATA AMENDMENT TO LICENSE NO		fred to
TELEPHONE NO.: AREA CODE (216)	4125 581	0500	Same Fee Cate Type of Date Che	Peory Foe G	ZIP CODE
ance with the general requireme Code of Federal Regulations, Po- license fee category should be s	ents contair arts 19, 20 tated in Ite	ned in Title 10, Code and 35 and the licen m 26 and the appro		tions Part 170.	the TK

	TEMS SIRED	MAXIMUM POSSESSION LIMITS (In millicuries)	ADDITIONAL ITEMS:	MAR ITEM DESIRI	S	MAXIMUM POSSESSION LIMITS (In millicuries)
10 CFR 31.11 FOR IN VITRO STUDIES			IODINE-131 AS IODIDE FOR TREAT	MENT		
10 CFR 35.100, SCHEDULE A, GROUP I		AS NEEDED	PHOSPHORUS 32 AS SOLUBLE PHOS FOR TREATMENT OF POLYCYTHER	AIN		
10 CFR 35.100, SCHEDULE A, GROUP II		AS NEEDED	PHOSPHORUS-32 AS COLLOIDAL CHROMIC PHOSPHATE FOR INTRACAVITARY TREAT- MENT OF MALIGNANT EFFUSIONS.			
10 CFR 35.100, SCHEDULE A, GROUP III						
10 CFR 35.100,SCHEDULE A, GROUP IV		AS NEEDED	GOLD-198 AS COLLOID FOR INTRA CAVITARY TREATMENT OF MALIG EFFUSIONS.	and the second second		
10 CFR 35.100, SCHEDULE A, GROUP V		AS NEEDED	IODINE-131 AS IODIDE FOR TREAT OF THYROID CARCINOMA	MENT		
10 CFR 35.100, SCHEDULE A, GROUP VI			XENON-133 AS GAS OR GAS IN SALINE FOR BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES.			

6.b. RADIOACTIVE MATERIAL FOR USES NOT LISTED IN ITEM 6.a. (Sealed sources up to 3 mCi used for calibration and reference standards are authorized under Section 35.14(d), 10 CFR Part 35, and NEED NOT BE LISTED.)

ELEMENT AND MASS NUMBER	PHYSICAL FORM	OF EACH FORM	DESCRIBE PURPOSE OF USE
new departmentPl	rston, D.O. a nt change.	s an authori	
0744010505 0/4	10 PP-		REGION III

CHEMICAL MAXIMUM NUMBER

NRC FORM 313M (9-81)

INFORMATION REQUIRED FOR !TEMS 7 THROUGH 23

For Items 7 through 23, check the appropriate box(es) and submit a	a detailed description of all the requested information. Begin
each item on a separate sheet. Identify the item number and the dat	e of the application in the lower right corner of each page. If
you indicate that an appendix to the medical licensing guide will be f	followed, do not submit the pages, but specify the revision
number and date of the referenced guide: Regulatory Guide 10.8	, Rev Date:

7. MEDICAL ISOTOPES COMMITTEE		15. GENERAL RULES FOR THE SAFE USE OF RADIOACTIVE MATERIAL (Check One)			
**********	Names and Specialties Attached; and		Appendix G Rules Followed; or		
	Duties as in Appendix B; or (Check One)		Equivalent Rules Attached		
	Equivalent Duties Attached		16. EMERGENCY PROCEDURES (Check One)		
8. 1	8. TRAINING AND EXPERIENCE		Appendix H Procedures Followed; or		
	Supplements A & B Attached for Each Individual User; and		Equivalent Procedures Attached		
Х	Refer to attached Item #8 Supplement A-Attached for RSC.	17. AREA SURVEY PROCEDURES (Check One)			
9. INSTRUMENTATION (Check One)			Appendix 1 Procedures Followed; or		
Х	Appendix C Form Attached; or		Equivalent Procedures Attached		
	List by Name and Model Number	18. WASTE DISPOSAL (Check One)			
10.	10. CALIBRATION OF INSTRUMENTS		Appendix J Form Attached; or		
	Appendix D Procedures Followed for Survey Instruments; or		Equivalent Information Attached		
	Equivalent Procedures Attached; and		19. THERAPEUTIC USE OF RADIOPHARMACEUTICALS (Check One)		
	Appendix D Procedures Followed for Dose Calibrator; or		Appendix K Procedures Followed; or		
	Equivalent Procedures Attached (Check One)		Equivalent Procedures Attached		
11. FACILITIES AND EQUIPMENT		20. THERAPEUTIC USE OF SEALED SOURCES			
Х	Description and Diagram Attached		Detailed Information Attached; and		
12. PERSONNEL TRAINING PROGRAM			Appendix L Procedures Followed; or (Check One)		
	Description of Training Attached		Equivalent Procedures Attached		
13. PROCEDURES FOR ORDERING AND RECEIVING RADIOACTIVE MATERIAL		21. PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE GASES (e.g., Xenon - 133)			
	Detailed Information Attached		Detailed Information Attached		
14.	PROCEDURES FOR SAFELY OPENING PACKAGES CONTAINING RADIOACTIVE MATERIALS (Check One)	122	PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL IN ANIMALS		
			Detailed Information Attached		
	Appendix F Procedures Followed; or	23.	PROCEDURES AND PRECAUTIONS FOR USE OF RADIOACTIVE MATERIAL SPECIFIED IN ITEM 6.6		
	Equivalent Procedures Attached	1	Detailed Information Attached		

		24. PERSONNEL MONITORIN	G DEVICES
(Check	TYPE appropriate box)	SUPPLIER	EXCHANGE FREQUENCY
	FILM		
WHOLE	TLD		
	OTHER (Specify)		
	FILM		
FINGER	TLD		
	OTHER (Specify)		
	FILM		
. WRIST	TLD		
	OTHER (Specify)		
	25. FO	R PRIVATE PRACTICE APPLIC	ANTS ONLY
. HOSPITAL	25. FO	R PRIVATE PRACTICE APPLICATION OF THE PRIVATE PRIVATE PRACTICE APPLICATION OF THE PRIVATE PRIV	E MATERIAL
MARKAGAM MARKETON STORY OF THE PARK	25. FO AGREEING TO ACCEPT PAT HOSPITAL	R PRIVATE PRACTICE APPLICATION OF THE PRIVATE PRIVATE PRACTICE APPLICATION OF THE PRIVATE PRIV	ANTS ONLY E MATERIAL b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.
MARKAGAM MARKETON STORY OF THE PARK	AGREEING TO ACCEPT PATHOSPITAL	TIENTS CONTAINING RADIOACTIVE	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR. c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAU
NAME OF	AGREEING TO ACCEPT PATHOSPITAL	R PRIVATE PRACTICE APPLICATIONS CONTAINING RADIOACTIVE	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR.
NAME OF	AGREEING TO ACCEPT PATHOSPITAL	TIENTS CONTAINING RADIOACTIVE	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR. c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECALTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.
MAILING CITY The applica	AGREEING TO ACCEPT PATHOSPITAL ADDRESS ant and any official executing to the second part of the 10 Code of Federal	STATE ZIP CODE 26. CERTIFICATE (This item must be completed by	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR. c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECALTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS.
MAILING CITY The applica	AGREEING TO ACCEPT PATHOSPITAL ADDRESS ant and any official executing to the second part of the 10 Code of Federal	STATE ZIP CODE 26. CERTIFICATE (This item must be completed by his certificate on behalf of the applicant Regulations, Parts 30 and 35, and that best of our knowledge and belief. REQUIRED	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR. c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECALTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS. applicant) separation lies in least 14 certify that this application is prepared in
MAILING CITY The applica conformity attached he	AGREEING TO ACCEPT PATHOSPITAL ADDRESS ant and any official executing to with Title 10, Code of Federal reto, is true and correct to the base of the second secon	STATE ZIP CODE 26. CERTIFICATE (This item must be completed by his certificate on behalf of the applicant Regulations, Parts 30 and 35, and that best of our knowledge and belief. REQUIRED	b. ATTACH A COPY OF THE AGREEMENT LETTER SIGNED BY THE HOSPITAL ADMINISTRATOR. c. WHEN REQUESTING THERAPY PROCEDURES, ATTACH A COPY OF RADIATION SAFETY PRECAUTIONS TO BE TAKEN AND LIST AVAILABLE RADIATION DETECTION INSTRUMENTS. applicant) in named in Item 1a certify that this application is prepared in Itali information contained herein, including any supplements to APPLICANT OR CERTIFYING/OFFICIAL (Signature) b. APPLICANT OR CERTIFYING/OFFICIAL (Signature) Therefore of Point)

NRC FORM 313M (9-81)

PRIVACY ACT STATEMENT

Pursuant to 5 U.S.C. 552a(e)(3), enacted into law by section 3 of the Privacy Act of 1974 (Public Law 93-579), the following statement is furnished to individuals who supply information to the Nuclear Regulatory Commission on NRC Form 313M. This information is maintained in a system of records designated as NRC-3 and described at 40 Federal Register 45334 (October 1, 1975).

- 1. AUTHORITY Sections 81 and 161(b) of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2111 and 2201(b)).
- 2. PRINCIPAL PURPOSE(S) The information is evaluated by the NRC staff pursuant to the criteria set forth in 10 CFR Parts 30-36 to determine whether the application meets the requirements of the Atomic Energy Act of 1954, as amended, and the Commission's regulations, for the issuance of a radioactive material license or amendment thereof.
- 3. ROUTINE USES The information may be used: (a) to provide records to State health departments for their information and use; and (b) to provide information to Federal, State, and local health officials and other persons in the event of incident or exposure, for their information, investigation, and protection of the public health and safety. The information may also be disclosed to appropriat Federal, State, and local agencies in the event that the information indicates a violation or potential violation of law and in the course of an administrative or judicial proceeding. In addition, this information may be transferred to an appropriate Federal, State, or local agency to the extent relevant and necessary for a NRC decision or to an appropriate Federal agency to the extent relevant and necessary for that agency's decision about you. A copy of the license issued will routinely be placed in the NRC's Public Document Room, 1717 H Street, N.W., Washington, D.C.
- 4. WHETHER DISCLOSURE IS MANDATORY OR VOLUNTARY AND EFFECT ON INDIVIDUAL OF NOT PROVIDING INFORMATION Disclosure of the requested information is voluntary. If the requested information is not furnished, however, the application for radioactive material license, or amendment thereof, will not be processed.
- 5. SYSTEM MANAGER(S) AND ADDRESS Director, Division of Fuel Cycle and Material Safety, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555.

NRC FORM 313M (9-81) NAME OF AUTHORIZED USER

AUTHORIZATION

Amend to add:

Guy R. Syverston, D.O.

Groups I, II, III
Iodine-131 for treatment
of hyperthyroidism and
cardiac dysfunction.

For physician training and experience, please refer to NRC license #34-17835-01.

Item #8
1 of 1 page
Prepared: 10/1/86
Lic. # 34-05382-01

APPENDIX C

INSTRUMENTATION

- 1. Survey meters (Amend to add)
 - a. Manufacturer's name: Bicron

Manufacturer's model number: Surveyor 50

Number of instruments available:

Minimum range: 0 mR/hr to 0.5 mR/hr

Maximum range: 0 mR/hr to 50 mR/hr

b. Manufacturer's name:

Manufacturer's model number:

Number of instruments available:

Minimum range: mR/hr to mR/hr

Maximum range: mR/hr to mR/hr

Dose Calibrator(s)

Manufacturer's name:

Manufacturer's model number:

Number of instruments available:

3. Instruments used for diagnostic procedures

Type of Instrument	Manufacturer's Name	Model No.
Amend to add:	-1-1	E V 2 0 0

Scintillation camera Picker 5X300
Amend to delete:

Scintillation camera Siemens 37GP
Scintillation camera Siemens LFOV

 Other (e.g., liquid scintillation counter, area monitor, velometer)

Item #9
1 of 1 page
Prepared: 10/1/86
Lic. #34-05382-01

FACILITIES AND EQUIPMENT DESCRIPTION

All radioactive sources are stored in such a manner (lead, concrete, refrigerator) so as to not exceed 2mR/hr at the surface of the barrier.

Mo-99/Tc-99m generator when used will be stored and eluted in the designated area. It will be shielded with lead bricks such that levels from all avenues of approach do not exceed 2.0mR/hr. Spent generators will be stored in the location identified in the attached diagram.

During elution, the eluate will be collected, assayed, and stored in a vial held in a quarter inch lead pig except during brief periods of transfer. Transfer of the eluate or portions of the eluate will be made by the use of syringes retained in lead shields designed for this purpose.

Eluates and compounds made from eluates will be drawn, synthesized, assayed and stored in lead vials or syringes such that levels as measured at contact with a low level survey meter do not exceed 2.0mR/hr except for brief periods during the actual transfer.

Radioactive materials obtained from radiopharmacy suppliers will be stored in their original shipping containers. If necessary, the doses will be placed behind additional shielding to reduce activity levels emitted from the container to 2mR/hr or less.

Syringe shields will be used on all accessories requiring the transfer of radiopharmaceuticals from vial to vial and in drawing up patient doses. Syringe shields will also be used in the administration of doses to patients except when the patient's well-being may be compromised. Under these circumstances, the dose containing syringes will be kept shielded up to the moment of injection.

Steps in the preparation of compounds requiring periods of heating, shaking, agitation or mixing will be performed utilizing lead shielding and/or mechanical or ultrasonic agitation equipment and/or remote handling devices (tongs, forceps, etc.) such that levels during the above period as measured by a low level survey meter do not exceed 2.0mR/hr.

Protective outer garments, such as laboratory coats and rubber gloves will be worn while handling radioactivity in uncontained form.

Item #11 l of 4 pages Prepared: 10/1/86 Lic. #34-05382-01 All possible set-ups will be made on easily cleanable trays. All trays and all other work surfaces will be covered with disposable absorbent paper.

decontamination kit will be maintained in the department. It will include the following items:

DECONTAMINATION KIT


PURPOSE ITEM posting of area Warning tape, chalk & signs 1. shoe covers, wet containers 2. Plastic bags, small hand protection Disposable gloves 3. fasten shoe covers, etc. 4. Masking tape safe handling 5. Forceps, tongs for contaminated material Large plastic bags Sponges, 4 x 4 sopping up blotting & drying Paper towels 8. detergent Radiac wash or detergent 9. friction 10. Scouring powder identification 11. Tags cut absorbent paper, etc. 12. Scissors taking swipes following 13. Whatman #1 filter paper decontamination cover area following 14. Chux decontamination

15. G-M survey meter

monitoring

Item #11 2 of 4 pages Prepared: 10/1/86 Lic. # 34-05382-01

FACILITIES AND EQUIPMENT DIAGRAM



Item 11 3 of 4 pages Prepared 10-1-86 Note that this is a new department for nuclear medicine. A close-out survey will be performed on the old department consisting of exposure rate measurements at all places where radioactive materials were used or stored. The average radiation levels associated with surface contamination or removable contamination will not exceed background. The survey will consist of the following:

- a. A diagram of the old facility with survey and wipe test results keyed to specific locations.
- b. The name of the person performing the survey.
- c. Date the survey was performed.
- d. The instrument(s) used for exposure rate measurements and analysis of wipes.
- e. Instrument calibration date.
- f. Background information.

The results of the close-out survey will be reviewed by our consultants (MIA Medical Physics Services) and retained in the department for future reference.

Item #11
Page 4 of 4
Prepared: 10/1/86
Lic.#34-05382-01

COMMON NO. 82536